Visiongain publishes Biosimulation Market Report 2020-2030

30 April 2020

Visiongain has launched a new pharma report Biosimulation Market Report 2020-2030: Forecasts by Product (Software, Services (In-house Services & Contract Services), Application (Drug Discovery, Drug Development, Others), End Use (Pharmaceutical & Biotechnology Companies, Academic Research Institutions, Regulatory Authorities, CROs), and Geography (North America, Latin America, Europe, Asia Pacific, MEA).

The global biosimulation market is anticipated to grow at a lucrative CAGR of xyz% and anticipated to reach USD xyz billion by 2020. Visiongain anticipates that the global biosimulation market is projected to grow on account of the growing adoption of biosimulation software by regulatory bodies, rising development of biologics & biosimilar, and growing usage of personalized medicines among other growth contributing factors.

To access the data contained in this document please email

BioPharma is plagued by large failure levels in clinical trials resulting in unacceptably low FDA acceptance rates and correspondingly large R&D costs. A major reason for this is the complexity of the disease and the lack of a full understanding of the mechanism by which the drug works. Although clinical trials attempt to select a homogeneous population, heterogeneity of the disease and drug complexity result in a high rate of failure.

Much of the manufactured goods, be they a semiconductor device, a fighter aircraft, or a drug-eluting stent, are designed and tested in software during their design process before being transported to production and production. This prevents expensive trial-and-error.

In brief, biosimulation is the capacity to anticipate the phenotype reaction of a human cell to external stimuli, such as a drug ligand or radiation. We use this tool to assess the patient's Therapy Reaction Table or TRI. The TRI care-naïve patient decides how the patient can respond to standard medication. For relapsed or refractory patients, TRI decides the optimal combination of approved FDA medications to which the patient can react.

In the year 2019, North America dominated the global biosimulation market owing to the presence of major pharmaceutical and biotechnology firms. The region is anticipated to continue its dominance over the forecast period owing to the growing number of research projects in the region, coupled with funding for research institutes from the government. Also, the market will continue to be driven by the existence of the target population, growing usage of personalized medicines, and increased R&D investment by important business organizations. Asia Pacific region is expected to experience the highest growth in terms of CAGR over the forecast period owing to the growing presence of cancer cases in markets such as India and China. Additionally, unmet needs of patients and untapped nations in this region have been attracting investments by global players and this is expected to boost the Biosimulation Market growth over the forecast period.

Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations, and launching new products to strengthen their position in the global biosimulation market. Companies are also expanding their R&D, distribution, and management facilities to expand their business and to hold a competitive edge in the Biosimulation Market.

The comprehensive market report features companies such as Advanced Chemistry Development, Inc., Certara USA, Inc., Chemical Computing Group, Inc., Dassault Systems SA, Entelos, Inc., Evidera, Inc., Genedata AG, InhibOx Ltd., Insilico Biotechnology AG, LeadInvent Technologies Pvt. Ltd., Leadscope, Inc., Physiomics PLC, Schrodinger, Inc., Simulation Plus, Inc., Rhenovia Pharma Ltd. among other prominent players. Also the research study offers market estimation and forecast for the period ranging 2020-2030 for global markets such as North America, Latin America, Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Russia, India, Japan, China, Australia, ASEAN, GCC and South Africa.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021


Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021


Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021


Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2021-2031

Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.

12 July 2021